Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$179,994 Mln
Revenue (TTM)
$29,443 Mln
Net Profit (TTM)
$8,510 Mln
ROE
0.4 %
ROCE
18.3 %
P/E Ratio
21.4
P/B Ratio
7.9
Industry P/E
--
EV/EBITDA
14.4
Div. Yield
2.2 %
Debt to Equity
1.1
Book Value
$18.1
EPS
$6.8
Face value
--
Shares outstanding
1,241,420,528
CFO
$115,888.00 Mln
EBITDA
$121,317.00 Mln
Net Profit
$75,750.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 15.1 | -9.0 | 16.4 | 25.9 | 22.3 | 17.0 | 4.7 |
|
BSE Sensex*
| -11.4 | -10.5 | -11.2 | -0.4 | 8.9 | 8.8 | 11.6 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
| 32.9 | 13.9 | -5.6 | 18.2 | 30.0 | -6.7 | 7.9 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gilead Sciences (GILD)
|
141.3 | 179,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 |
| 208.3 | 388,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 351.5 | 197,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 | |
| 59.4 | 120,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 918.1 | 881,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 | |
| 237.3 | 582,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 920.4 | 116,133.4 | 397,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 | |
| 114.5 | 285,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 149.8 | 296,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 | |
| 27.3 | 151,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey,... Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Read more
Chairman & CEO
Mr. Daniel P. O'Day
Chairman & CEO
Mr. Daniel P. O'Day
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Gilead Sciences Inc (GILD) is $141.29 (NASDAQ) as of 18-Mar-2026 16:28 EDT. Gilead Sciences Inc (GILD) has given a return of 22.26% in the last 3 years.
The P/E ratio of Gilead Sciences Inc (GILD) is 21.35 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.07
|
6.80
|
|
2024
|
242.28
|
6.02
|
|
2023
|
17.96
|
4.46
|
|
2022
|
23.63
|
5.11
|
|
2021
|
14.72
|
4.35
|
The 52-week high and low of Gilead Sciences Inc (GILD) are Rs 157.29 and Rs 93.37 as of 19-Mar-2026.
Gilead Sciences Inc (GILD) has a market capitalisation of $ 179,994 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Gilead Sciences Inc (GILD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-3.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.